Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Koen van Besien

Showing results (51-60 of 241) with videos related to

Pageof 25
Sort By:
Leukemia & Lymphoma|June 2, 2020
Busulfan or melphalan: is there a better conditioning regimen for allogeneneic transplantation?Jingmei Hsu, Koen Van Besien, Frédéric Baron
The New England Journal of Medicine|January 18, 2013
Peripheral-blood versus bone marrow stem cellsKoen van Besien, Tsiporah Shore, Melissa Cushing
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2011
T-cell-depleted reduced-intensity conditioning transplantation for lymphoma: do donor lymphocyte infusions really matter?Koen van Besien, Vaishalee Kenkre, Andrew S Artz
British Journal of Haematology|February 21, 2006
Order of patient entry influences outcome for metastatic renal cell cancer after non-myeloablative allogeneic stem cell transplantationAndrew S Artz, Masha Kocherginsky, Koen Van Besien
Chimerism|March 21, 2013
Microchimerism and allogeneic transplantation: we need the proof in the puddingKoen van Besien, Hong-Tao Liu, Andrew Artz
Current Treatment Options in Oncology|June 22, 2005
Therapeutic options for patients with Hodgkin's disease and non-Hodgkin's lymphoma who relapse after autologous transplantKoen van Besien, Sonali Smith, Hillard M Lazarus
Blood|June 5, 2002
Reduced duration of cytopenias following melphalan conditioning and autografting for multiple myelomaSteven M Devine, Balkrishna Jahagirdar, Koen van Besien
Seminars in Oncology|March 23, 2011
Personalized treatment of lymphoma: promise and realityErika Ramsdale, Koen van Besien, Sonali M Smith
Leukemia & Lymphoma|April 25, 2007
Interdigitating dendritic cell tumors in two patients exposed to topical calcineurin inhibitorsMelinda K Gordon, Madeleine Kraus, Koen van Besien
Leukemia & Lymphoma|July 10, 2020
Hematological manifestations of COVID-19Alain Mina, Koen van Besien, Leonidas C Platanias
Pageof 25

Showing results (51-60 of 241) with videos related to

Sort By:
Pageof 25
Leukemia & Lymphoma|June 2, 2020
Busulfan or melphalan: is there a better conditioning regimen for allogeneneic transplantation?Jingmei Hsu, Koen Van Besien, Frédéric Baron
The New England Journal of Medicine|January 18, 2013
Peripheral-blood versus bone marrow stem cellsKoen van Besien, Tsiporah Shore, Melissa Cushing
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2011
T-cell-depleted reduced-intensity conditioning transplantation for lymphoma: do donor lymphocyte infusions really matter?Koen van Besien, Vaishalee Kenkre, Andrew S Artz
British Journal of Haematology|February 21, 2006
Order of patient entry influences outcome for metastatic renal cell cancer after non-myeloablative allogeneic stem cell transplantationAndrew S Artz, Masha Kocherginsky, Koen Van Besien
Chimerism|March 21, 2013
Microchimerism and allogeneic transplantation: we need the proof in the puddingKoen van Besien, Hong-Tao Liu, Andrew Artz
Current Treatment Options in Oncology|June 22, 2005
Therapeutic options for patients with Hodgkin's disease and non-Hodgkin's lymphoma who relapse after autologous transplantKoen van Besien, Sonali Smith, Hillard M Lazarus
Blood|June 5, 2002
Reduced duration of cytopenias following melphalan conditioning and autografting for multiple myelomaSteven M Devine, Balkrishna Jahagirdar, Koen van Besien
Seminars in Oncology|March 23, 2011
Personalized treatment of lymphoma: promise and realityErika Ramsdale, Koen van Besien, Sonali M Smith
Leukemia & Lymphoma|April 25, 2007
Interdigitating dendritic cell tumors in two patients exposed to topical calcineurin inhibitorsMelinda K Gordon, Madeleine Kraus, Koen van Besien
Leukemia & Lymphoma|July 10, 2020
Hematological manifestations of COVID-19Alain Mina, Koen van Besien, Leonidas C Platanias
Pageof 25